The National Institutes of Health (NIH) Evidence-based Methodology Workshop was sponsored by the Office of Disease Prevention and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. A multidisciplinary steering committee developed the workshop agenda. The NIH Library created an extensive bibliography on polycystic ovary syndrome (PCOS) to facilitate workshop discussion. During the 2½-day workshop, invited experts discussed the body of evidence and attendees had opportunities to provide comments during open discussion periods. After weighing the evidence, an unbiased, independent panel prepared this report, which summarizes the workshop and identifies future research priorities.

Introduction

Polycystic ovary syndrome (PCOS) is a common hormone disorder that affects approximately 5 million women of reproductive age in the United States. Women with PCOS have difficulty becoming pregnant (i.e., are infertile) and may have high levels of androgen hormones from the ovary and adrenal gland. Other organ systems that can be affected by PCOS include the brain, pancreas, liver, muscle, blood vasculature, and fat.

In addition to fertility impairment, a woman with PCOS may have some of the following symptoms and findings:

- Irregular or no menstrual periods in women of reproductive age (ovulatory dysfunction)
- Acne
- Weight gain
- Excess hair growth on the face and body (hirsutism)
- Thinning scalp hair
- Ovarian cysts (polycystic ovarian morphology)
- Mental health problems.

Women with PCOS are often resistant to the biological effects of insulin and, as a consequence, may have high insulin levels. Women with PCOS are at risk for type 2 diabetes, high cholesterol, and high blood pressure. Obesity also appears to worsen the
condition. The degree of obesity may vary by ethnicity. Costs to the U.S. healthcare system to identify and manage PCOS are approximately $4 billion annually; however, this estimate does not include treatment of the serious conditions associated with PCOS.

For most of the 20th century, PCOS was a poorly understood condition. In 1990, the National Institutes of Health (NIH) held a conference on PCOS to create both a working definition of the disorder and diagnostic criteria. The outcome of this conference, the NIH Criteria, served as a standard for researchers and clinicians for more than a decade. In 2003, a consensus workshop in Rotterdam in the Netherlands developed new diagnostic criteria, the Rotterdam Criteria. The Androgen Excess (AE) and PCOS Society proposed the AE-PCOS Criteria in 2006.

On December 3–5, 2012, the NIH sponsored the Evidence-based Methodology Workshop on Polycystic Ovary Syndrome. The panel was asked to clarify:

1. The benefits and drawbacks of different diagnostic criteria
2. The causes, predictors, and long-term consequences of PCOS

1. Benefits and Drawbacks of Different Diagnostic Criteria

Over the past 2 decades, the use of the NIH Criteria, the Rotterdam Criteria, and the AE-PCOS Society Criteria have been useful in understanding the syndrome. The individual components of these criteria are difficult to measure, and it is not clear how each contributes to the outcomes of concern. Table 1 shows the criteria proposed by these authoritative bodies. Table 2 demonstrates the overlapping and nonexclusive phenotypes included in the three currently used classification criteria. The use of multiple classification systems is confusing and delays progress in understanding the syndrome. It also hinders the ability of clinicians to partner with women to address and manage the health issues that concern them. Each of these diagnostic criteria has inherent strengths and weaknesses (see Table 3).

<table>
<thead>
<tr>
<th>Table 1. Diagnostic Criteria for PCOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Chronic anovulation</td>
</tr>
<tr>
<td>• Clinical and/or biochemical signs of hyperandrogenism (with exclusion of other etiologies, e.g., congenital adrenal hyperplasia) (Both criteria needed)</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Table 2. Potential Phenotypes of PCOS by NIH 1990, Rotterdam 2003, and AE-PCOS 2006

<table>
<thead>
<tr>
<th>Panel Terminology</th>
<th>Diagnostic Criteria</th>
<th>NIH</th>
<th>AE-PCOS/ Rotterdam 1</th>
<th>Rotterdam 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Androgen Excess</td>
<td>Hyperandrogenemia</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Hyperandrogenism*</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Ovulatory Dysfunction</td>
<td>Oligo-anovulation</td>
<td>+</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>Polycystic Ovarian Morphology</td>
<td>Polycystic Ovaries</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
</tbody>
</table>

*Clinical signs or symptoms of excess androgen.


Table 3. Strengths and Limitations of Diagnostic Criteria

<table>
<thead>
<tr>
<th>Diagnostic Criteria</th>
<th>Strengths</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Androgen Excess</td>
<td>• Included as a component in all major classifications</td>
<td>• Measurement is performed only in blood.</td>
</tr>
<tr>
<td></td>
<td>• A major clinical concern for patients</td>
<td>• Concentrations differ during time of day.</td>
</tr>
<tr>
<td></td>
<td>• Animal models employing androgen excess resemble but do not fully mimic human disease</td>
<td>• Concentrations differ with age.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Normative data are not clearly defined.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assays are not standardized across laboratories.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clinical hyperandrogenism is difficult to quantify and may vary by ethnic group.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Tissue sensitivity is not assessed.</td>
</tr>
</tbody>
</table>
Table 3. Strengths and Limitations of Diagnostic Criteria (continued)

<table>
<thead>
<tr>
<th>Diagnostic Criteria</th>
<th>Strengths</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovulatory Dysfunction</td>
<td>• Included as a component in all major classifications</td>
<td>• Normal ovulation is incompletely understood.</td>
</tr>
<tr>
<td></td>
<td>• A major clinical concern for patients</td>
<td>• Normal ovulation varies over a woman’s lifetime.</td>
</tr>
<tr>
<td></td>
<td>• Infertility a common clinical complaint</td>
<td>• Ovulatory dysfunction is difficult to measure objectively.</td>
</tr>
<tr>
<td>Polycystic Ovarian Morphology</td>
<td>• Historically associated with syndrome</td>
<td>• Technique dependent</td>
</tr>
<tr>
<td></td>
<td>• May be associated with hypersensitivity to ovarian stimulation</td>
<td>• Difficult to obtain standardized measurement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lack of normative standards across the menstrual cycle and lifespan (notably in adolescence) as ovarian morphology varies with age</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Technology required to accurately image not universally available</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Imaging possibly inappropriate in certain circumstances (e.g., adolescence)</td>
</tr>
</tbody>
</table>

2. Causes, Predictors, and Long-Term Consequences of PCOS

The etiology of the syndrome is multifactorial and involves interactions between “nature” and “nurture.” Androgens appear to be clearly implicated in the pathogenesis based on animal models and clinical presentation. Prenatal testosterone exposure in animal models results in many, but not all, of the characteristics of this syndrome.

A variety of observations, including concordance in monozygotic twins, strongly suggests a genetic component. Recent genome-wide association studies (GWAS) have identified candidate genes that merit further study. Epigenetic factors and environmental factors, such as obesity, appear to exacerbate any underlying genetic predisposition. The extent to which obesity or its associated insulin resistance contributes to the syndrome, independently or collectively, is not known.

The impact of the syndrome on an individual varies significantly based on several factors, such as the severity of the components, comorbidities, and life course considerations. In addition, each individual experiences the syndrome in the context of her own reproductive health, metabolic, and quality-of-life concerns (see Table 4). Hirsutism, obesity, and infertility are common complaints. This syndrome also is associated with metabolic dysfunction, including diabetes. However, it is unclear whether these abnormalities increase the incidence of cardiovascular events or other diabetic complications. The relationship between the syndrome and other metabolic abnormalities, sleep apnea, depression, anxiety, and quality of life remains to be
defined by longitudinal studies. Given the prevalence of this syndrome worldwide, these important public health issues deserve more attention.

**Table 4.** Common Clinical Manifestations Associated With the Syndrome Across the Life Course and Types of Research Recommended

<table>
<thead>
<tr>
<th>CLINICAL CONCERNS</th>
<th>Prenatal</th>
<th>Childhood</th>
<th>Adolescence</th>
<th>Reproductive Years</th>
<th>Peri- and Post-Menopause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oligo-ovulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression and Anxiety</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infertility</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RESEARCH AGENDA**

| Basic + Translational Research | ✓       | ✓   | ✓   | ✓   | ✓   |
| Randomized Trials of Therapies |         | ✓   | ✓   | ✓   | ✓   |
| Longitudinal Outcome Studies   |          |     | ✓   | ✓   | ✓   |
| Family Studies                 |          |     |     |     |     |

The PCOS Australian Alliance evaluated the quality of the published evidence on PCOS in 2011 and published a 1,100-page evidence appraisal document based on 22 separate systematic reviews and more than 38,000 articles from around the world (www.managingpcos.org.au/pcos-evidence-based-guidelines).

### 3. Optimal Prevention and Treatment Strategies

Because the underlying pathophysiology of PCOS is not fully determined, treatment is currently directed at symptoms rather than targeting a specific etiologic pathway. Lifestyle modification and weight reduction have been shown to decrease androgen effects, increase ovulation, and improve insulin sensitivity. Metformin decreases androgen levels but has demonstrated only modest effect on fertility and has little effect on insulin action. Preliminary studies suggest that thiazolidinediones improve insulin action but do not alter ovarian function. Clomiphene and aromatase inhibitors increase fertility but can lead to multiple pregnancy and do not alter other metabolic or psychosocial manifestations of the syndrome. Surgery has been shown to improve
fertility and transiently affect ovarian function. Ovarian gonadotropin stimulation can improve ovarian function in PCOS in the cycle treated, but therapy is fraught with increased risks for multiple births and ovarian hyperstimulation syndrome (OHSS). OHSS is a potentially fatal risk of advanced reproductive therapies in women with PCOS. Anti-androgens may mitigate but do not resolve hirsutism.

Patients with PCOS and obstructive sleep apnea (OSA) can be treated with continuous positive airway pressure (CPAP), which also may ameliorate metabolic dysfunction. However, it is not known if any of these treatments alter the natural history of this syndrome or its components. It also is not known whether screening for and subsequent treatment of associated abnormalities, such as OGTT-diagnosed diabetes, reduces chronic morbidity or mortality.

In summary, the panel has identified the following major areas as critical in the advancement of our understanding of the syndrome.

Panel Recommendations

1. We believe the name “PCOS” is a distraction and an impediment to progress. It causes confusion and is a barrier to effective education of clinicians and communication with the public and research funders. The name focuses on a criterion—polycystic ovarian morphology—which is neither necessary nor sufficient to diagnose the syndrome. We believe it is time to recognize the advances that have been made since the description of the syndrome by Irving F. Stein, Sr., and Michael L. Leventhal. It is time to expeditiously assign a name that reflects the complex metabolic, hypothalamic, pituitary, ovarian, and adrenal interactions that characterize the syndrome—and their reproductive implications. The right name will enhance recognition of this major public health issue for women, educational outreach, “branding,” and public relations and will assist in expanding research support.

2. We recommend maintaining the broad, inclusionary diagnostic criteria of Rotterdam (which includes the “classic NIH” and AE-PCOS criteria) while specifically identifying the phenotype:

- Androgen Excess + Ovulatory Dysfunction
- Androgen Excess + Polycystic Ovarian Morphology
- Ovulatory Dysfunction + Polycystic Ovarian Morphology
- Androgen Excess + Ovulatory Dysfunction + Polycystic Ovarian Morphology

* Oral glucose tolerance test.
The specific phenotypes should be reported explicitly in all research studies and clinical care. This recommendation should be disseminated to journal editors, funding sources, and professional societies.

3. We recommend the following:
   a. Improve the methods and criteria used to assess androgen excess.
      - Develop a precise, accurate, and traceable assay for androgen levels.
      - Define normal ranges for different ethnic groups and age groups.
      - Record the conditions under which the sample is drawn (e.g., time of day, time of menstrual cycle).
      - Clearly define the criteria used for the clinical diagnosis of androgen excess, including variability based on ethnicity.
   b. Improve the methods and criteria used to assess ovulatory dysfunction.
      - Clearly define the criteria used to diagnose oligomenorrhea, amenorrhea, and anovulation.
      - Establish normal ranges across the age spectrum and across populations.
   c. Improve the methods and criteria used to assess polycystic ovarian morphology.
      - Develop methods to define polycystic morphology accurately and precisely.
      - Establish normal ranges across the age spectrum and across populations.

4. We believe that the involvement of consumers in the guideline development of the Australian task force and the engagement of primary care providers, multidisciplinary teams, and patients in education and programmatic roll-out is a model worthy of imitation.

5. We recommend several important research and clinical priorities:
   a. Conduct adequately powered, carefully phenotyped, multiethnic cohort studies to establish the genetic or epigenetic cause(s) of the syndrome.
   b. Establish the prevalence of abnormal glucose tolerance in women wishing to conceive, and determine whether treatment of abnormal
glucose tolerance prior to or early post-conception alters maternal-fetal outcomes.

c. Conduct translational research to determine the mechanisms by which the syndrome alters ovarian, hypothalamic-pituitary-adrenal, and metabolic function to establish model systems that can be used to identify novel therapeutic approaches.

d. Conduct sufficiently large, well-controlled epidemiologic studies determining the prevalence, phenotypes, and morbidities of PCOS in multiethnic longitudinal studies to determine:

   i. If the syndrome is associated with increased cardiovascular and diabetic complications.

   ii. If the risk of these cardiovascular and diabetic complications (or the lack thereof) is associated with specific phenotypes.

   iii. If treatment of metabolic abnormalities reduces the risk of cardiovascular and diabetic complications.

  e. Conduct suitably powered studies to determine if the syndrome is associated with endometrial, breast, and ovarian cancers, and, if so, determine optimal prevention, detection, and treatment.

  f. Identify optimal therapies to treat the most common symptoms and patient complaints of the syndrome, such as hirsutism and obesity.

  g. Identify optimal therapies and best practices to achieve successful pregnancy.

6. Establish multidisciplinary programs to improve public and healthcare provider awareness and management for women who currently have the syndrome.
Workshop Panel Members

Timothy R.B. Johnson, M.D., FACOG
Arthur F. Thurnau Professor
Bates Professor of the Diseases of
Women and Children and Chair
Department of Obstetrics and Gynecology
Obstetrician-Gynecologist-in-Chief
Professor of Women’s Studies and Research
Professor
Center for Human Growth and Development
Faculty Associate
Center for Global Health
University of Michigan
Ann Arbor, Michigan

Lorrie Kline Kaplan, CAE
Executive Director
American College of Nurse-Midwives
Silver Spring, Maryland

Pamela Ouyang, M.B.B.S.
Professor of Medicine
Johns Hopkins University School of Medicine
Deputy Director
Institute for Clinical and Translational
Research
Director
Women’s Cardiovascular Health Center
Cardiologist
Johns Hopkins Bayview Medical Center
Baltimore, Maryland

Robert A. Rizza, M.D.
Executive Dean for Research
Research Administrative Services
Mayo Clinic
Rochester, Minnesota
Speakers

David H. Abbott, Ph.D.
Professor
Department of Obstetrics and Gynecology
Wisconsin National Primate Research Center
University of Wisconsin
Madison, Wisconsin

Silva Arslanian, M.D.
Chief
Weight Management and Wellness Center
Director
Pediatric Clinical and Translational Research Center
University of Pittsburgh Medical Center
(UPMC) Richard L. Day Endowed Chair in Pediatrics
Professor of Pediatrics
University of Pittsburgh School of Medicine
Children’s Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania

Ricardo Azziz, M.D., M.P.H., M.B.A.
Professor
Obstetrics, Gynecology, and Medicine
President
Georgia Health Sciences University
Chief Executive Officer
Georgia Health Sciences Health System
Augusta, Georgia

Adam Balen, M.B.B.S., M.D., D.Sc., FRCOG
Consultant Obstetrician and Gynaecologist and Subspecialist in Reproductive Medicine
Honorary Professor of Reproductive Medicine and Surgery
Leeds General Infirmary and St. James’s University Hospital
The Leeds Teaching Hospitals NHS Trust
University of Leeds
Leeds
United Kingdom

Kurt T. Barnhart, M.D., M.S.C.E.
William Shippen, Jr. Professor of Obstetrics and Gynecology and Epidemiology
Director
Women’s Health Clinical Research Center
Division of Reproductive Endocrinology and Infertility
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania

Shalender Bhasin, M.D.
Professor of Medicine
Boston University School of Medicine
Chief
Section of Endocrinology, Diabetes, and Nutrition
Director
Boston Claude D. Pepper Older Americans Independence Center
Boston Medical Center
Boston, Massachusetts

Marcelle I. Cedars, M.D.
Professor and Director
Division of Reproductive Endocrinology
University of California, San Francisco
San Francisco, California

R. Jeffrey Chang, M.D.
Professor and Director
Division of Reproductive Endocrinology
Department of Reproductive Medicine
University of California, San Diego
School of Medicine
La Jolla, California

PonJola Coney, M.D.
Senior Associate Dean for Faculty Affairs
Virginia Commonwealth University
School of Medicine
Richmond, Virginia

Adrian S. Dobs, M.D., M.H.S.
Professor of Medicine and Oncology
Division of Endocrinology and Metabolism
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Daniel Dumesic, M.D.
Division Chief and Professor, Reproductive Endocrinology and Infertility
Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, California

Andrea Dunaif, M.D.
Charles F. Kettering Professor of Endocrinology and Metabolism
Vice Chair for Research
Department of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

David A. Ehrmann, M.D.
Professor of Medicine and Associate Director
University of Chicago Clinical Research Center
Director
Center for Polycystic Ovary Syndrome
University of Chicago Medical Center
Chicago, Illinois

Bart C.J.M. Fauser, M.D., Ph.D.
Professor of Reproductive Medicine
Utrecht Life Sciences
University Medical Center
Utrecht
The Netherlands

Jose C. Florez, M.D., Ph.D.
Assistant Physician in Endocrinology
Center for Human Genetic Research
Diabetes Unit
Massachusetts General Hospital
Associate Professor
Harvard Medical School
Associate Member
Broad Institute
Boston, Massachusetts

Stephen Franks, M.D., FRCP, FMedSci
Professor
Institute of Reproductive and Developmental Biology
Imperial College London
Hammersmith Hospital
London
United Kingdom

Richard S. Legro, M.D., FACOG
Professor of Obstetrics and Gynecology
College of Medicine
Milton S. Hershey Medical Center
Hershey Obstetrics and Gynecology
The Pennsylvania State University
Hershey, Pennsylvania

Rogerio A. Lobo, M.D.
Professor of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons
New York, New York

John C. Marshall, M.B.Ch.B., M.D.
Director
Center for Research in Reproduction
University of Virginia School of Medicine
Charlottesville, Virginia

Sue Moenter, Ph.D., M.S.
Professor
Departments of Molecular and Integrative Physiology, Internal Medicine, and Obstetrics and Gynecology
University of Michigan School of Medicine
Ann Arbor, Michigan

Robert Norman, M.D.
Director
Robinson Institute
Faculty of Health Sciences
University of Adelaide
Adelaide
Australia
Sharon E. Oberfield, M.D.
Professor of Pediatrics and Director
Division of Pediatric Endocrinology, Diabetes, and Metabolism
Columbia University Medical Center
New York, New York

Vasantha Padmanabhan, Ph.D.
Professor
Departments of Pediatrics, Obstetrics and Gynecology, Molecular and Integrative Physiology, and Environmental Health Sciences
University of Michigan School of Medicine
Ann Arbor, Michigan

Natalie Rasgon, M.D., Ph.D.
Professor
Department of Psychiatry and Behavioral Sciences
Stanford Center for Neuroscience in Women’s Health
Stanford University School of Medicine
Stanford, California

Teresa Sir-Petermann, M.D.
Professor
Laboratory of Endocrinology and Metabolism, West Division
University of Chile School of Medicine
Santiago
Chile

Evelyn O. Talbott, Dr.P.H., M.P.H.
Professor
Department of Epidemiology
Program Director
Environmental Epidemiology Program
Graduate School of Public Health
University of Pittsburgh
Pittsburgh, Pennsylvania

Nancy Terry, M.L.S.
Biomedical Research Librarian/Informationist
National Institutes of Health Library
Division of Library Services
Office of Research Services
Office of the Director
National Institutes of Health
Bethesda, Maryland

Margrit Urbanek, Ph.D.
Associate Professor
Division of Endocrinology
Department of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Okan Bülent Yildiz, M.D.
Professor
Department of Internal Medicine
Endocrinology and Metabolism Unit
Hacettepe University School of Medicine
Ankara
Turkey
Steering Committee

Chairperson: Louis V. DePaolo, Ph.D.
Chief
Reproductive Sciences Branch
Center for Population Research
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institutes of Health
Bethesda, Maryland

R. Jeffrey Chang, M.D.
Professor and Director
Division of Reproductive Endocrinology
Department of Reproductive Medicine
University of California, San Diego
School of Medicine
La Jolla, California

Patrice Desvigne-Nickens, M.D.
Medical Officer
Heart Failure and Arrhythmias
Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

Adrian S. Dobs, M.D., M.H.S.
Director
Johns Hopkins Clinical Research Network
Professor of Medicine and Oncology
Division of Endocrinology and Metabolism
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Andrea Dunaif, M.D.
Charles F. Kettering Professor of Endocrinology and Metabolism
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Olga Epifano, Ph.D.
Health Specialist
Behavioral and Social Sciences Research Branch
National Institute of Dental and Craniofacial Research
National Institutes of Health
Bethesda, Maryland

Lucia Hindorff, Ph.D., M.P.H.
Epidemiologist
Office of Population Genomics
National Human Genome Research Institute
National Institutes of Health
Rockville, Maryland

Maren Laughlin, Ph.D.
Senior Advisor for Integrative Metabolism
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Bethesda, Maryland

Barbara Linder, M.D., Ph.D.
Senior Advisor for Childhood Diabetes Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Bethesda, Maryland

Rogerio Lobo, M.D.
Professor of Obstetrics and Gynecology
Center for Women’s Reproductive Care
Columbia University College of Physicians and Surgeons
New York, New York

Steering Committee members provided their input at a meeting held October 24–25, 2011. The information provided here was accurate at the time of that meeting.
Workshop Sponsors

_Eunice Kennedy Shriver National Institute of Child Health and Human Development_
Alan E. Guttmacher, M.D.
Director

_Office of Disease Prevention_
David M. Murray, Ph.D.
Director